DXR

Daxor Corporation (DXR) | Rumor.io

Daxor

DXR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,945

Bullish sentiment (50-day avg)100%

Price to earnings ratio6.72

Market capitalization66.3M

Earnings per share1.69

Dividend yield (TTM)0.54%

Revenue (annual)10.3M

Net income (annual)9.2M

Social

What share of all stock conversation is about DXR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Nov 17

Daxor Corporation's ($DXR) new analyzer is patented and FDA-cleared, enabling precision measurement of blood volume.
The company is addressing a multi-billion-dollar healthcare crisis by developing a solution for a broad range of common conditions.
Daxor's technology has the potential for accelerated market expansion in the precision medicine space.

Generated by AI

Sentiment

Of the messages about DXR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +4.55
Bearish	—	—	—	0% -4.55

Bullish· Aug 7

The company's low float of 2.1 million shares, combined with significant news, could drive the price to $20.00 to $30.00.
The news of FDA approval is game-changing and has the potential to pump the stock price, especially with a low float and increasing institutional involvement.
The stock has been tightly held and has seen a steady climb, with a potential for further upside if a large group buys up the available shares, potentially reaching $20.00 to $30.00.

Bearish· Nov 2

$DXR's recent volume drop suggests the run is over, with a possible price drop to $5 by the end of the week.
A large number of sell orders are being placed on Level 2, indicating a potential price drop, with the possibility of DXR falling below $7 before the end of the day.
The company's leadership sold shares in March for over $16, raising concerns that they may have sold again at the current price, which could be a major red flag for investors.

Generated by AI

Topics

Of the messages about DXR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.46%
Analysts	—	0%	0%	11.54%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Announcements· May 22

Daxor Corporation has priced a $4.0 million underwritten public offering of 410,000 shares at $9.75 per share.
The company's stock price declined 20% in premarket trading after announcing the proposed public offering.
Daxor Corporation has issued a press release announcing the pricing of the underwritten public offering, which is expected to raise $4.0 million.

Technical Analysis· Oct 30

$DXR has a possible descending triangle breakout with targets at 10.32 and 12.59 if it gets the necessary volume.
A double bottom pattern is forming in $DXR, which could lead to a price increase above 7.
$DXR has a new level to break at 6.50, which could lead to a price increase above 7 if it is successfully broken.

Generated by AI

Community

Of the messages about DXR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	56.67%
Newcomers	—	0%	0%	43.33%

Regulars· Nov 17

Daxor's new analyzer has been patented and cleared, positioning the company for accelerated market expansion in precision medicine.
The new analyzer addresses the multi-billion-dollar silent crisis in healthcare, the need to precisely measure blood volume.
Daxor's focus is on tackling the need for precise blood volume measurement in a broad range of common and critical care applications.

Newcomers· May 22

The newcomer is focused on the significant decline of $DXR by -21.73% today, with an unusually high trading volume.
The newcomer is discussing the announced proposed underwritten public offering and its impact on Daxor Corporation's stock price, with a 20% decline premarket.
The newcomer is speculating on whether $DXR will continue to fall, asking others to comment on their reasons.

Generated by AI

Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026. Management will host one-on-one and small group meetings with investors. For more information about the event or questions about registration, interested pa

21d agoca.finance.yahoo.com

Daxor reports 16% kit sales growth, expands sales team

28d agoInvesting.com

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, “It’s still Day 1.” — Jeff BezosThat's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our c

29d agoYahoo Finance

Also Discussed

Investors talking about DXR also mention

#	Name	Attention
1	Arcadia Biosciences Inc.RKDA	0.01%0
2	Origin Agritech Ltd.SEED	0%new
3	Avalon Holdings Corp. Class A Common StockAWX	0%new
4	My Size, Inc.MYSZ	0%new
5	OptimumBank Holdings Inc.OPHC	0%0
6	Pyxis Tankers Inc.PXS	0%0
7	Geron CorporationGERN	0%0
8	Comstock Holding Companies, Inc.CHCI	0%0
9	ZW Data Action Technologies Inc.CNET	0%0
10	CASI - CASI Pharmaceuticals, Inc.	——

Daxor Corporation

Healthcare
Medical Instruments & Supplies

Daxor Corporation is a medical instrumentation and biotechnology company focused on blood volume measurement and blood volume analysis. Daxor Corporation develops and manufactures the BVA-100 Blood Volume Analyzer, a diagnostic system designed to provide precise, objective measurement of a patient’s blood volume status and composition. Its products are used in clinical settings that support patient management across critical care, surgery, cardiology, nephrology, and other medical specialties where accurate fluid assessment is important. The company also offers related diagnostic and laboratory services through its IDANT division, including autologous blood storage and andrology services such as semen analysis, sperm washing, and general lab testing. Based in Oak Ridge, Tennessee, Daxor Corporation serves healthcare providers with tools intended to improve blood volume assessment and diagnostic decision-making.

Website

Location

109 Meco Lane

Oak Ridge, TN, 37830

United States

Social

What share of all stock conversation is about DXR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Nov 17

Daxor Corporation's ($DXR) new analyzer is patented and FDA-cleared, enabling precision measurement of blood volume.
The company is addressing a multi-billion-dollar healthcare crisis by developing a solution for a broad range of common conditions.
Daxor's technology has the potential for accelerated market expansion in the precision medicine space.

Generated by AI

Sentiment

Of the messages about DXR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +4.55
Bearish	—	—	—	0% -4.55

Bullish· Aug 7

The company's low float of 2.1 million shares, combined with significant news, could drive the price to $20.00 to $30.00.
The news of FDA approval is game-changing and has the potential to pump the stock price, especially with a low float and increasing institutional involvement.
The stock has been tightly held and has seen a steady climb, with a potential for further upside if a large group buys up the available shares, potentially reaching $20.00 to $30.00.

Bearish· Nov 2

$DXR's recent volume drop suggests the run is over, with a possible price drop to $5 by the end of the week.
A large number of sell orders are being placed on Level 2, indicating a potential price drop, with the possibility of DXR falling below $7 before the end of the day.
The company's leadership sold shares in March for over $16, raising concerns that they may have sold again at the current price, which could be a major red flag for investors.

Generated by AI

Topics

Of the messages about DXR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	88.46%
Analysts	—	0%	0%	11.54%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0%

Announcements· May 22

Daxor Corporation has priced a $4.0 million underwritten public offering of 410,000 shares at $9.75 per share.
The company's stock price declined 20% in premarket trading after announcing the proposed public offering.
Daxor Corporation has issued a press release announcing the pricing of the underwritten public offering, which is expected to raise $4.0 million.

Technical Analysis· Oct 30

$DXR has a possible descending triangle breakout with targets at 10.32 and 12.59 if it gets the necessary volume.
A double bottom pattern is forming in $DXR, which could lead to a price increase above 7.
$DXR has a new level to break at 6.50, which could lead to a price increase above 7 if it is successfully broken.

Generated by AI

Community

Of the messages about DXR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	56.67%
Newcomers	—	0%	0%	43.33%

Regulars· Nov 17

Daxor's new analyzer has been patented and cleared, positioning the company for accelerated market expansion in precision medicine.
The new analyzer addresses the multi-billion-dollar silent crisis in healthcare, the need to precisely measure blood volume.
Daxor's focus is on tackling the need for precise blood volume measurement in a broad range of common and critical care applications.

Newcomers· May 22

The newcomer is focused on the significant decline of $DXR by -21.73% today, with an unusually high trading volume.
The newcomer is discussing the announced proposed underwritten public offering and its impact on Daxor Corporation's stock price, with a 20% decline premarket.
The newcomer is speculating on whether $DXR will continue to fall, asking others to comment on their reasons.

Generated by AI

Daxor

Social

Nov 17

Sentiment

Bullish· Aug 7

Bearish· Nov 2

Topics

Announcements· May 22

Technical Analysis· Oct 30

Community

Regulars· Nov 17

Newcomers· May 22

News

Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

Daxor reports 16% kit sales growth, expands sales team

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Also Discussed

Daxor Corporation

Company Information

Location

News

Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

Daxor reports 16% kit sales growth, expands sales team

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Also Discussed

Social

Nov 17

Sentiment

Bullish· Aug 7

Bearish· Nov 2

Topics

Announcements· May 22

Technical Analysis· Oct 30

Community

Regulars· Nov 17

Newcomers· May 22